Physician profile
Danielle Demarest
NPI 1306674239
$819.16
in general payments reported to CMS, 2019-2025
11 companies · $782 in 2025
The $782 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $37.26 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $155.88 | 2025 | Attruby |
| Atricure, INC. | $146.93 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Madrigal Pharmaceuticals | $136.27 | 2025 | Rezdiffra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.87 | 2025 | Lifevest |
| Boston Scientific Corporation | $86.40 | 2025 | General - Therapies |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.92 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $47.37 | 2025 | Farxiga, Lokelma |
| Kiniksa Pharmaceuticals International, Plc | $37.26 | 2024 | Arcalyst |
| Pfizer INC. | $18.28 | 2025 | |
| Scpharmaceuticals INC. | $18.20 | 2025 | |
| Novartis Pharmaceuticals Corporation | $15.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Demarest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.